Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion.
Sales increased due to an 8.5% increase in revenue within the U.S. Healthcare Solutions segment and a 10.5% increase in revenue within the International Healthcare Solutions segment.
“Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities,” said Robert Mauch, President and CEO of Cencora.
Also Read: Oscar Health Well-Positioned To Manage Market Reset, Eyes Profitability In 2026
U.S. Healthcare Solutions revenue was $72.9 billion in the third quarter of fiscal 2025, up 8.5% due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss …